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Abnormal reward prediction-error signalling in antipsychotic
naive individuals with ﬁrst-episode psychosis or clinical risk for
psychosis
Anna O. Ermakova 1,2, Franziska Knolle 1,2, Azucena Justicia1,3, Edward T. Bullmore 1,2,3, Peter B. Jones 1,2,3, Trevor W. Robbins2,4,
Paul C. Fletcher1,2,3,5 and Graham K. Murray1,2,3
Ongoing research suggests preliminary, though not entirely consistent, evidence of neural abnormalities in signalling prediction
errors in schizophrenia. Supporting theories suggest mechanistic links between the disruption of these processes and the
generation of psychotic symptoms. However, it is unknown at what stage in the pathogenesis of psychosis these impairments in
prediction-error signalling develop. One major confound in prior studies is the use of medicated patients with strongly varying
disease durations. Our study aims to investigate the involvement of the meso-cortico-striatal circuitry during reward prediction-
error signalling in earliest stages of psychosis. We studied patients with ﬁrst-episode psychosis (FEP) and help-seeking individuals
at-risk for psychosis due to sub-threshold prodromal psychotic symptoms. Patients with either FEP (n= 14), or at-risk for developing
psychosis (n= 30), and healthy volunteers (n= 39) performed a reinforcement learning task during fMRI scanning. ANOVA revealed
signiﬁcant (p < 0.05 family-wise error corrected) prediction-error signalling differences between groups in the dopaminergic
midbrain and right middle frontal gyrus (dorsolateral prefrontal cortex, DLPFC). FEP patients showed disrupted reward prediction-
error signalling compared to controls in both regions. At-risk patients showed intermediate activation in the midbrain that
signiﬁcantly differed from controls and from FEP patients, but DLPFC activation that did not differ from controls. Our study conﬁrms
that FEP patients have abnormal meso-cortical signalling of reward-prediction errors, whereas reward-prediction-error dysfunction
in the at-risk patients appears to show a more nuanced pattern of activation with a degree of midbrain impairment but preserved
cortical function.
Neuropsychopharmacology (2018) 0:1–9; https://doi.org/10.1038/s41386-018-0056-2
INTRODUCTION
The cognitive basis of psychotic symptoms remains unknown, but
abnormalities in the processing of prediction error have been
proposed to contribute to the development of psychotic
symptoms [1, 2]. A prediction error is the discrepancy between
something we expect to happen (e.g. receiving a reward after a
chosen stimulus), based on experience (e.g. we have received a
reward after selecting this stimulus on prior occasions), and what
actually happens (e.g. no reward is provided). Prediction errors
help us to update our expectations and can lead to allocation of
attention and attribution of salience to stimuli, which may drive
subsequent learning [3, 4]. Faulty prediction-error signalling could
lead to several maladaptive psychological processes that have
been proposed to contribute to the generation of psychotic
symptoms: aberrant assignment of attention and motivational
importance to innocuous stimuli, and disrupted associative
learning leading to the formation of irrelevant associations and
eventually delusions [5–9].
Several studies have attempted to examine the neural basis of
prediction-error abnormalities in psychosis, and have documented
blunted midbrain, striatal and/or cortical encoding of reward
prediction errors [10–13] and non-reward-related prediction errors
[14]. Our previous work in psychosis patients has identiﬁed meso-
cortico-striatal prediction-error deﬁcits, involving midbrain, stria-
tum and frontal cortex, especially right dorsolateral prefrontal
cortex (DLPFC) [12, 14]. Dopaminergic neurons in the midbrain,
which project heavily to the striatum as well as to the cortex, have
been found to code reward prediction errors [15]. Meso-cortical-
striatal regions, including the right DLPFC, are activated during
associative learning in functional Magnetic Resonance Imaging
(fMRI) studies, especially when expectations are violated, and the
fMRI signal scales with prediction-error magnitude [16–19]. Work
from our group and others has supported this view by showing
differences in the right DLPFC between patients and controls [12,
18, 20]. Dysfunction of these regions may manifest in abnormal-
ities in learning and motivational salience [21–23], potentially
contributing to the development of psychosis [24]. However, a
major complication in the interpretation of patient studies is that
several studies are potentially confounded by having either all, or
the majority of patients, taking antipsychotic medication, which
Received: 7 December 2017 Revised: 12 March 2018 Accepted: 13 March 2018
1Department of Psychiatry, University of Cambridge, Cambridge, UK; 2Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK; 3Cambridgeshire
and Peterborough NHS Foundation Trust, Cambridge, UK; 4Department of Psychology, University of Cambridge, Cambridge, UK and 5Institute of Metabolic Science, University of
Cambridge, Cambridge, UK
Correspondence: Graham K. Murray (gm285@cam.ac.uk)
These authors contributed equally: Anna O. Ermakova, Franziska Knolle.
www.nature.com/npp
© American College of Neuropsychopharmacology 2018
has been shown to modulate brain-reward processing in healthy
individuals and patients [25–27]. Given this, and the likely
importance of dopaminergic dysfunction in the pathogenesis of
psychosis [28], it is critical to investigate possible abnormalities
during reward prediction-error processing in antipsychotic naive
patient samples. To our knowledge, only two studies [13, 29] have
examined reward prediction-error signalling in unmedicated, but
not all antipsychotic naive, samples of mixed ﬁrst episode and
chronic schizophrenia patients (average age 27 years [13], average
age 34 years [29]). Although both of these studies document
striatal reward prediction-error abnormalities, neither study report
abnormalities in the dopaminergic midbrain. This is of particular
interest given that the extensive evidence for the role of
dopamine in both prediction-error signalling [15, 30] and the
pathophysiology of psychosis.
Some studies of chronic medicated schizophrenia patients have
shown intact prediction error-associated brain signals [10, 31, 32].
It is possible that these neural abnormalities, as well as related
behavioural manifestations of altered learning, may be more
prominent early in the course of the illness, especially in
antipsychotic naive samples [5, 12, 13, 29]. Establishing the
pathophysiological abnormalities at the very earliest stages of
illness is likely to be critical for optimal treatment and preventative
interventions. The onset of psychosis is usually preceded by a
prodromal phase involving social, educational or occupational
decline accompanied by prodromal symptoms such as suspicious-
ness or hallucinations without a delusional interpretation [33].
Help-seeking patients with these features have been shown to
have increased risk for developing psychotic illness, and have
been termed to have at-risk mental states (ARMS) or be at “ultra-
high clinical risk” of psychosis [33]. The prodromal phase may offer
a critical period for intervention to improve long-term prognosis.
The study of at-risk patients has proved a useful paradigm to
investigate some of the earliest pathophysiological changes in
schizophrenia and related illness [34]. Brain prediction-error
signalling has not been examined in this group before, although
there is some evidence for abnormal cortical and/or striatal
processing of salience [35, 36] or reward anticipation in at-risk
patients [37, 38]. Given the theoretical importance of prediction
error in learning and the pathogenesis of symptoms, we reasoned
that it is key to examine brain prediction-error signals in the
earliest possible stages of psychosis. In this study, we set out to
examine fMRI-correlates of reward prediction errors in a sample of
patients with ﬁrst-episode pyschosis (FEP) and in at-risk patients,
all naive to antipsychotic medication, with a particular focus on
the midbrain, striatum and right DLPFC.
A simple view of the continuum of psychosis is that at-risk
patients with sub-threshold symptoms will show similar pathology
to clinical psychosis but of lesser severity [39] and there is
evidence in support of this [34]. We therefore hypothesised that
Table 1. Sample characteristics for healthy controls, for participants at-risk and with FEP
At-risk FEP Controls Statistical test results
Mean SD Mean SD Mean SD
Age 22.03 3.30 23.57 5.80 23.23 3.53 F(2,82)= 1.07, p= 0.35
IQ 105.53 13.86 103.46 15.88 113.47 11.15 F(2,80)= 4.48, p= 0.014
Mother’s education 1.80 1.56 2.43 1.79 2.18 1.41 F(2,82)= 0.94, p= 0.39
Gender (m/f) 16/14 7/7 19/20 χ2 (2)= 0.15, p= 0.93
Handedness (r/h) 26/4 10/4 35/4 χ2 (2)= 2.84, p= 0.24
Smoking (yes/no) 15/15 9/5 12/27 χ2 (2)= 5.55, p= 0.06
Antidepressants (yes/no) 8/30 4/14 1/39 χ2 (2)= 9.58, p= 0.008
Mean SD Mean SD Mean SD Statistical test results
Alcohol 2.53 1.00 1.50 1.45 2.59 0.68 F(2,82)= 7.13, p= 0.001
Cannabis 1.03 1.12 1.36 1.60 0.95 0.97 F(2,82)= 0.65, p= 0.52
Hallucinogens 0.30 0.53 0.29 0.47 0.28 0.56 F(2,82)= 0.01, p= 0.99
Stimulants 0.50 0.63 0.71 0.82 0.46 0.79 F(2,82)= 0.61, p= 0.55
Depressants/opiates 0.13 0.43 0.07 0.27 0.10 0.38 F(2,81)= 0.13, p= 0.88
BDI 24.86 14.06 26.45 8.20 T= 0.35, df= 37, p= 0.73
PANSS positive 11.07 3.17 16.07 4.92 T= 4.4, df= 42, p < 0.001
PANSS negative 9.03 3.71 9.29 4.77 T= 0.19, df= 42 p= 0.85
CAARMS total psychosis score 15.10 6.75 23.86 6.48 T= 4.1, df= 42, p < 0.001
UTC 2.0 2.08 3.71 2.46 T= 2.39, df= 42, p= 0.02
UTC Freq 1.76 1.92 3.21 2.15 T= 2.23, df= 42, p= 0.03
NBI 3.10 1.37 4.64 1.64 T= 3.26, df= 42, p= 0.002
NBI Freq 3.13 1.33 4.00 1.41 T= 1.97. df= 42, p= 0.06
PA 2.83 1.82 4.57 1.50 T= 3.11, df= 42, p= 0.001
PA Freq 2.27 1.68 3.71 1.49 T= 2.76, df= 42, p= 0.009
Psychopathology scales were compared across the patient groups only. Use of alcohol and other drugs was measured on a ﬁve-point scale (alcohol use: 0—
none, 1—not more than three times, 2—occasional user, 3—regular user (1–3 times weekly), 4—frequent user (almost every day)); drug use: 0—never tried, 1
—not more than three times, 2—occasional user, 3—regular user (1–3 times weekly), 4—frequent user (almost every day)
Comprehensive Assessment of At-Risk Mental States (CAARMS) subscales: Unusual Thought Content (UTC), Non-Bizarre Ideas (NBI), Perceptual Abnormalities
(PA); total psychosis on CAARMS was calculated as the sum of the intensity and frequency of UTC, NBI and PA subscales. Statistical tests were conducted across
three groups for the demographic variables and substance use. The two clinical groups were compared on psychiatric groups
BDI Beck Depression Inventory, GAF Global Assessment of Functioning, f frequency, Χ2 Pearson’s chi-square, F ANOVA F-statistic, H Kruskal–Wallis test statistic,
SD standard deviation
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patients with FEP would have abnormal prediction-error activity in
the dopaminergic midbrain, striatum and right DLPFC compared
to controls, and that at-risk patients would have brain prediction-
error activation patterns intermediate between FEP patients and
controls.
METHODS
Participants
The study was approved by the Cambridgeshire three National
Health Service research ethics committee. Individuals with FEP (n
= 14, average 23.57 years, 7 female) or at-risk for psychosis
individuals (n= 30, average 22.03 years, 14 female) were recruited
from the Cambridgeshire ﬁrst-episode psychosis service, CAMEO.
Inclusion criteria were as follows: age 16–35 years, early psychosis
as reﬂected by meeting either at-risk attenuated psychotic
symptoms criteria according to the Comprehensive Assessment
of At-risk Mental States (CAARMS, [33]) or FEP criteria. Patients
with FEP were required to meet ICD-10 criteria for a schizophrenia
spectrum disorder (F20, F22, F23, F25, F28, F29) or affective
psychosis (F30.2, F31.2, F32.3), to be within 1 year of ﬁrst
presentation to the clinical service for psychosis, and to have
ongoing positive psychotic symptoms (see Supplementary Mate-
rial for details of diagnostic breakdown in the FEP group); all
participants were required to be naive to antipsychotic medica-
tion. Healthy volunteers (n= 39, average 23.23 years, 20 female)
without a history of psychiatric illness or brain injury were
recruited as control subjects. All subjects had normal or corrected-
to-normal vision and no contraindications to MRI-scanning. None
of the participants had a recreational drug or alcohol dependence.
Healthy volunteers did not report any personal or family history of
signiﬁcant neurological, psychiatric or medical disorders, and were
matched to patients regarding age, gender, handedness and
maternal level of education. There were no signiﬁcant differences
between groups in age, sex, handedness or recreational drug use
(Table 1). Antidepressant medication was taken by one control
(sertraline), four FEP (two ﬂuoxetine and two sertraline) and eight
ARMS (two ﬂuoxetine, two citalopram, one sertraline, one
amitriptyline (low dose), two unknown). The use of antidepres-
sants differed signiﬁcantly between controls and patients (Table 1,
see supplements for description of effect of antidepressant on
behavioural performance and imaging results). We used the
Culture Fair matrices test, which is a general IQ measure. There
was a signiﬁcant difference between groups in IQ. The three
groups were not intended to be fully matched on IQ, as cognitive
impairment is common in psychosis, and the task is not
intellectually taxing. However, the groups were matched in
maternal education, which indicates intellectual potential was
matched. Even though the groups slightly differed in IQ, we did
not ﬁnd group differences in the performance. Furthermore, we
did not ﬁnd signiﬁcant correlations between performance and IQ
in any of the trial types. Therefore, we are conﬁdent that the group
difference observed in our sample is due to psychiatric differences
rather than differences in IQ. On average, the patients had
predominantly positive psychotic symptoms (it was an entry
requirement to have some degree of current positive symptoms)
and low levels of negative symptoms. FEP had signiﬁcantly more
severe symptoms than the at-risk group. Use of alcohol and other
Fig. 1 Behavioural task. a The three different trial types and feedback probabilities. b The experimental task, including trial timing
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drugs was measured on a ﬁve-point scale from (Table 1). The
control subjects, a typical group of healthy young adults, tend to
drink slightly more alcohol than the patients. Our clinical
experience suggests that patients from our service, many of
whom have paranoia and/or social anxiety, and some of whom
have negative symptoms, socialise less frequently than controls.
This may partly explain why the patient groups consume less
alcohol. No signiﬁcant correlations between use of alcohol and
performance or brain signalling were detected. Written informed
consent was supplied by all participants.
fMRI reward task
During the fMRI-scan, participants performed a probabilistic
monetary learning task (Fig. 1) that required them to choose
between two abstract visual stimuli (fractal pictures) displayed on
a computer screen, to maximise pay-offs [12, 26, 40, 41]. On each
trial, the participant chose one of two stimuli, then feedback was
provided. From the feedback, the participant learnt which of the
pictures were more likely to give a reward of £1, or a loss of £1,
and which ones were neutral. Each one of the three pairs of stimuli
were presented in 30 trials (90 randomised trials in total per
subject). The stimuli within each pair led to a speciﬁc outcome
with different probabilities: Reward trials: one picture led to a £1
win in 80% of trials and to neutral feedback in 20% of trials, the
other picture led to a neutral outcome in 80% of trials and to a £1
win in 20% of trials; bivalent trials: there was a 50% chance of
either losing or winning £1 [41]; neutral trials: 80%/20% chance of
receiving two kinds of neutral feedback (Fig. 1a). The order of the
pictures presented and the position of the high-probability
stimulus were counterbalanced across trials of the same valence
and pseudo-randomised. To win money, the participants had to
learn by trial and error, to learn which stimulus was more likely to
produce a reward. The participants were informed that any money
won during the experiment would be paid to them at the end of
the study.
Behavioural analysis
A 3×3 mixed-model analysis of variance (ANOVA, group × trial
type) was used to investigate the group differences in reaction
times and stimuli choices in the three types of trials (reward,
bivalent and neutral). We examined the proportion of “correct”
responses. Here the term “correct” means selecting the picture
that leads to a high probability of getting £1 in the reward trial,
and the picture with the higher probability of receiving the blue
feedback picture in neutral trials, and is randomly assigned to
choosing one of the pictures in bivalent trials (Fig. 1a). In the
bivalent and neutral trials, the assignment of “correctness” is
arbitrary, but assigning one stimulus in each category to be the
“correct” stimulus allows examination of whether participants
preferred one stimulus over another and the extent to which
response patterns differed across trial types.
fMRI data acquisition and analysis
Full details of our 3T scanning protocol and analysis methods are
available in the Supplementary Material.
The seven explanatory variables (regressors) that we used were
as follows: (1) onset of the bivalent cues; (2) onset of the neutral
cues; (3) onset of the reward cues; (4) neutral outcome onsets
(neutral feedback) during both neutral and reward trials; (5)
winning outcome onset in the reward trials; (6) winning outcome
onset in the bivalent trials; (7) loss outcome onset in bivalent trials.
All regressors were modelled as 2 s events and convolved with a
canonical double-gamma response function. We added temporal
derivatives to the model to account for possible variation in the
haemodynamic response function and we included motion
parameters.
Our contrast of interest aimed at detecting activation associated
with positive prediction error, and follows a contrast originally
used by Seymour and colleagues who employed a similar
paradigm in a healthy volunteer study to examine positive
prediction error [41]. We contrasted winning £1 in bivalent trials
versus winning £1 in reward trials; contrasting these identical
outcomes in the context of different expectations represents a
measure of positive prediction error. On the reward trials the
reward is well predicted and elicits a low, yet still positive,
prediction error; however, the outcome is unpredictable on
bivalent trials and hence elicits a high positive prediction error
[41]. Therefore, contrasting the two events gives a measure of
high versus low prediction error, and hence provides an assay of
prediction-error brain activation. This prediction-error contrast has
the advantage that it is perfectly balanced in terms of outcome
value; hence it is unconfounded by reward outcome value or
valence, which has been proposed to be a potential confound of
alternative approaches, particularly in designs where reward
prediction error and reward value are collinear [42, 43].
For the group ANOVA analysis, we used this prediction-error
contrast of interest as the outcome variable (FSL software calls
outcome variables COPES: contrast of parameter estimates) and
group as the predictor variable. We used permutation based
statistics using the FSL tool randomise, utilising threshold-free-
cluster enhancement, which enhances cluster-like structures but
remains fundamentally a voxel-wise statistical testing method [44].
We report results at p= 0.05 or less, family-wise error corrected for
multiple comparisons, using the variance smoothing option (3
mm) as recommended for experiments with modest sample sizes,
as is common in fMRI research [45]. Our main analysis was based
on a region of interest approach as follows. Our primary region of
interest was the dopaminergic midbrain using the probabilistic
atlas [46], in which traditional anatomical segmentation was
replicated using a seed-based functional connectivity approach
and which provides a mask that includes substantia nigra and
ventral tegmental area. The probabilistic map used to assess
midbrain activation has been reliably used in a number of studies
[47, 48]. In our two secondary regions of interest, we investigated
the associative and limbic striatum (using a single hand-drawn
mask, encompassing both associative and limbic striatum, based
on operational criteria [49, 50]), and the right DLPFC (utilising a
sphere, 10 mm, centred at x= 50, y= 30, z= 28, based on our
previous work [14]. Supplementary Figure 1 shows our primary
and secondary regions of interest. As ANOVA will show whether
the groups deviate from each other, it does not show the direction
of effects. We therefore planned that for any voxels deemed
signiﬁcant in the ANOVAs, we would proceed to planned paired
group comparisons, again using FSL randomise to test our
hypothesis that on the contrast of interest, the following pattern
would be seen: controls > at-risk > FEP). For each individual, we
also extracted contrast values (contrast of parameter estimates, or
COPEs in FSL) from voxels in which signiﬁcant group differences
were found, and calculated cluster averages; the extracted values
were used for correlations with symptoms (within group), for bar
charts of group differences and, as a supplement to our randomise
paired group tests, to further test our hypothesis of controls > at-
risk > FEP.
In support of this initial analysis and results, we also ran an
additional analysis with a general linear model where a prediction-
error regressor was determined by a computational Q-learning
model as we and others have used previously [12, 26, 40]
(methods and results reported in Supplementary Material).
RESULTS
Behaviour results: choices
On analysis of “correct” choices across trial type and group, there
was a main effect of trial type (F= 20.93, df= 2.160, p < 0.001), but
no effect of group (F= 1.10, df= 2.80, p= 0.34) or group by trial
type interaction (F= 1.53, df= 4.160, p= 0.20; see Fig. 2). The
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probability of choosing the “correct” stimulus increased in the
course of the experiment (for a display of learning curves for each
condition see Supplementary Figure 2A–C). Bonferroni-corrected
post-hoc tests showed that participants chose the “correct”
stimulus more frequently in reward trials than in neutral (p <
0.001), or bivalent (p < 0.001), with no difference between neutral
and bivalent trials (p= 0.7). Participants learned to choose the
picture that most often led to winning £1 (high-probability
stimulus: “correct” response) in the majority of reward trials (mean
percentage of “correct” choices 75%), whereas performance on
other trials was similar to chance (neutral trials 55%, bivalent trials
52%).
To investigate whether participants used the feedback to make
an informed decision, further demonstrating engagement in the
task, we conducted a win-stay lose-shift analysis (Supplementary
Figure 3). We conducted a repeated measure ANOVA with 2 (win
stay, lose shift) × 3 (reward, bivalent, neural) analysis across
groups. Across all trial types and groups, we found a signiﬁcantly
higher stay probability after a rewarded (in the case of neutral:
colour matching) trial compared to lose-shifting on unrewarded
(non-matching) trials (win stay: 69.01% ± 1.62, lose shift: 43.69% ±
1.70; F= 75.56, df= 1.80, p < 0.001). There was a signiﬁcant trial
type effect (F= 6.0, df= 2, p= 0.003), as well as win stay/lose shift
by group interaction (F= 8.40, df= 1.2, p < 0.001), a win stay/lose
shift by trial type interaction (F= 32.79, df= 1.2, p < 0.001), and a
marginally signiﬁcant trial type by group interaction (F= 2.26, df
= 2.2, p= 0.065).
In our planned group comparisons (Supplementary Table 1 and
Supplementary Figure 3), we found that controls had a
signiﬁcantly higher probability for a win stay behaviour than FEP
patients on reward and neutral trial types (reward trials: p= 0.027;
neutral trials: p= 0.012) and marginally on bivalent trials (p=
0.062). Controls and at-risk patients were similarly likely to repeat
the same response after a win. At-risk patients had a signiﬁcantly
higher probability of win stay behaviour in neutral trials compared
to FEP (p= 0.013), but the two patient groups did not differ on the
other trial types. FEP patients had a higher probability for a lose
shift behaviour compared to controls and at-risk patients in both
reward and neutral trials (reward trials: FEP > controls: p= 0.001,
FEP > at-risk: p= 0.008; neutral trials: FEP > controls: p= 0.001,
FEP > at-risk: p= 0.045). Controls and at-risk patients were
similarly likely to shift after a loss.
Behaviour results: reaction times
We analysed reaction times trial type and group. We found a
signiﬁcant main effect of trial type (F= 4.473, df= 2.160, p= 0.01),
but no effect of group (F= 0.32, df= 2.80, p= 0.73) or group by
trial type interaction (F= 1.28, df= 4.160, p= 0.28). The
Bonferroni-corrected post-hoc tests revealed that participants
independent of group reacted signiﬁcantly (p < 0.001) faster to
reward trials (1122.83 ms ± 33.31) than to bivalent trials (1358.99
ms ± 41.49), and similarly (p= 0.14) to neutral trials (1329.30 ms ±
97.87).
Prediction-error imaging results: ANOVA across three groups
We conducted second level (i.e. group level) ANOVAs using FSL
randomise across the three groups across the whole brain and in
Fig. 2 Trial performance: percentage of “correct” (high-likelihood)
choices stratiﬁed by trial type and participant group. Error bars are ±
1 SE
Fig. 3 Group differences in region of interest analysis of activation associated with reward prediction-error signal (p < 0.05 FWE-corrected)
across the three groups (controls, ﬁrst-episode psychosis and at-risk patients) in the midbrain ventral tegmental area (right panel, z=−12),
and right middle gyrus/dorsolateral prefrontal cortex (left panel, z= 22). Colour bar depicts corrected voxel p-value from 0.001 (yellow) to 0.05
(red)
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our region of interests. Our outcome measure presented here in
the main manuscript text is the contrast value (in FSL termed
contrast of parameter estimates, or COPE) of a bivalent trial win
versus a reward trial win, which corresponds to positive reward
prediction error; group is the predictor variable. Results from a
related outcome variable—prediction error-associated brain
activity derived from the computationally modelled prediction
error—are presented in the Supplementary Material, and are
similar. On whole-brain analysis, there were no group differences
that passed our statistical threshold corrected for multiple
comparisons.
Primary region of interest results: prediction-error imaging results
in the dopaminergic midbrain
We found a signiﬁcant family-wise-error corrected main effect for
group in the primary region of interest, the dopaminergic
midbrain (maximal difference at x=−4, y=−12, z=−12; t=
3.45, p= 0.013 FWE-corrected, 39 voxels; Fig. 3). For each of these
39 signiﬁcant voxels, family-wise error correcting for multiple
comparisons, we performed planned group comparisons between
pairs of groups using randomise to test our hypothesis of controls
> at-risk patients > FEP patients. The results were consistent with
the hypothesis (Fig. 4): at-risk patients were intermediate and
signiﬁcantly differed from both FEP patients and controls
(controls > at-risk patients maximal difference at x= 0, y=−16,
z=−8; t= 2.86, p= 0.033 FWE-corrected, 3 voxels; at-risk > FEP
patients, maximal difference at x=−4, y=−8, z=−12; t= 3.25,
p= 0.007 FWE-corrected, 26 voxels). There was a signiﬁcant
difference between controls and FEP patients (controls > FEP,
maximal difference at x= 0, y=−16, z=−8; t= 4.63, p < 0.001
FWE-corrected, 39 voxels). Another way to follow-up the
signiﬁcant effect of group in the ANOVA to test our hypothesis
of brain prediction-error signal following the pattern controls > at-
risk patients > FEP patients, is by taking the prediction-error
contrast value average for all 39 voxels that were signiﬁcant in the
ANOVA, and conducting planned paired group comparisons. This
analysis also revealed that at-risk patients (mean= 0.66, SD=
54.86) were intermediate between the FEP patients and the
controls, having a signiﬁcantly smaller contrast value than
controls: controls > at-risk patients, p= 0.034, one-tailed; but
signiﬁcantly greater than in FEP: at-risk > FEP patients, p= 0.001,
one-tailed. The mean contrast value in the controls (mean= 24.44,
SD= 50.12) was signiﬁcantly greater than in FEP (mean=−55.03,
SD= 50.70): controls > FEP, p < 0.001, one-tailed, conﬁrming our
hypothesis of controls > at-risk patient > FEP patients. In conclu-
sion, these results show highest midbrain signalling in response to
positive reward prediction error in controls, intermediate signal-
ling in ARMS and lowest in FEP.
Secondary region of interest prediction-error imaging results
No voxels passed our threshold on ANOVA in the associative-
limbic striatum. There was a signiﬁcant family-wise-error corrected
group effect in the right DLPFC (maximal difference at x= 50, y=
26, z= 20; t= 3.53, p= 0.018 FWE-corrected, 20 voxels; Fig. 3). For
each of these 20 signiﬁcant voxels, family-wise error correcting for
multiple comparisons, we performed planned two-group compar-
isons between using randomise to test our hypothesis of controls
> at-risk patients > FEP patients. The results were not consistent
with the hypothesis (Fig. 4). Although we found a signiﬁcant
difference between controls and FEP patients (controls > FEP,
maximal difference at x= 50, y= 24, z= 20; t= 3.72, p < 0.001
FWE-corrected, 20 voxels), and between at-risk and FEP patients
(at-risk > FEP, maximal difference at x= 50, y= 26, z= 20; t= 4.46,
p < 0.001 FWE-corrected, 20 voxels), controls and at-risk patients
did not differ signiﬁcantly. We complemented the voxel based
paired group comparisons with an analysis taking the prediction-
error contrast value average for all 20 voxels in the DLPFC that
were signiﬁcant in the ANOVA, and conducting planned paired
group comparisons to test our hypothesis of brain prediction-error
signal following a pattern (controls > at-risk patients > FEP
patients). This analysis was consistent with the voxel-wise paired
group comparisons in that it did not support our hypothesis: the
mean contrast values for these 20 voxels in controls (mean=
32.90, SD= 62.82) were signiﬁcantly greater than in FEP (mean=
−45.13, SD= 48.40): controls > FEP, p < 0.001, though not differ-
ent from at-risk patients (mean= 36.29, SD= 53.03): controls > at-
risk patients, p= 0.81. Mean contrast values in at-risk patients
were signiﬁcantly greater than in FEP (p < 0.001). These results
show strong DLPFC activation in response to positive reward
prediction error in controls, and nearly identical signalling in
ARMS, but a signiﬁcant deactivation in FEP.
As an explorational analysis, we analysed the left DLPFC, and we
did not ﬁnd any signiﬁcant effect (p > 0.25).
Symptom correlations
There were no signiﬁcant correlations between midbrain or DLPFC
activation total CAARMS symptom severity in FEP (midbrain rho=
0.03, p= 0.93; DLPFC rho=−0.27, p= 0.34) or the at-risk group
(midbrain rho= 0.18, p= 0.33; DLPFC rho= 0.233, p= 0.21).
Correlations with participants’ characteristics
No signiﬁcant correlations between use of alcohol and perfor-
mance, reaction times or brain signalling were detected.
DISCUSSION
We show evidence of signiﬁcantly reduced midbrain signalling of
reward prediction errors in patients with FEP and at-risk for
psychosis. In addition, we also report DLPFC abnormalities in
patients with FEP, showing that abnormalities associated with
prediction-error processing in psychotic illness are not restricted
Fig. 4 Bar chart shows the mean prediction-error contrast values
(termed contrast of parameter estimates, or COPEs in FSL) according
to the group, extracted from the signiﬁcant clusters determined by
FSL randomised ANOVA results. The contrast values (COPEs) are
derived from the contrast between Reward win and Bivalent win,
which constitute the reward prediction error. Error bars show ± 1 SE;
a.u. arbitrary units. *p < 0.05
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to sub-cortical regions, consistent with previous results [12, 14,
51]. These results are not secondary to antipsychotic medication,
because people with current or previous prescriptions of these
drugs were excluded. Therefore, our ﬁndings extend previous
ﬁndings reporting abnormal reward prediction-error signalling in
the midbrain, striatum and cortex in a partly medicated sample of
FEP patients (in which results held in a very small unmedicated
subsample) [12], in medicated samples of schizophrenia patients
[10, 11], and in the cortex and striatum of unmedicated, but not
antipsychotic naive, samples of mixed FEP and chronic schizo-
phrenia patients (mean age 27 years [13] or mean age 34 years
[29]). We note that one previous study [25] tested an unmedi-
cated, antipsychotic naive, schizophrenia sample and also
reported midbrain alterations in a reward-associated task; this
study, however, focussed on anticipation of reward and punish-
ment rather than reward prediction error. To our knowledge, our
study is, therefore, the ﬁrst to document abnormal brain
prediction-error signals in the dopaminergic midbrain with early-
stage psychosis in an entirely antipsychotic naive sample.
Our study is also the ﬁrst to examine reward prediction-error
signalling in patients at-risk for developing psychosis, and as such
it will require replication before deﬁnitive conclusions can be
drawn, especially as there were only very small areas of difference
in the at-risk patients. We found a mild abnormality in midbrain
prediction-error signalling in the at-risk group that was inter-
mediate in severity between psychotic illness and controls.
Although the prediction-error signal in the dorsolateral prefrontal
cortex was also disrupted in FEP patients, dorsolateral prefrontal
cortex prediction-error signalling was relatively spared in the at-
risk group, contrary to our hypothesis. These ﬁndings were similar
in both the contrast-based prediction-error analysis presented in
the main manuscript text, and in the alternative computationally
informed approach presented in the Supplementary Material.
Conﬂicting evidence exists as to whether the same pathological
mechanisms are responsible for both prodromal (sub-threshold)
and severe psychotic symptoms [39]. Under the straightforward
account of a dimensional theory of psychosis [52], the same
pathology responsible for severe psychotic symptoms in schizo-
phrenia should also be present (to a milder degree) in people with
sub-threshold psychotic symptoms such as suspicions or mild
hallucinations. Such an account would posit that people at-risk for
psychosis due to the presence of sub-threshold psychotic
symptoms would be characterised by a level of pathophysiological
disruption that is of similar nature but lesser severity than the
ﬂorid illness. The ﬁndings of the present study provide some
support this theory for the dopaminergic midbrain, analogous to
the pattern seen in a previous PET imaging study in the striatum
[34]. However, we did not ﬁnd signiﬁcant associations with
symptoms scores, which would be expected by a dimensional
account. Another possibility, however, is that there may be
qualitative differences in the pathology of sub-threshold and
severe psychosis [53], which needs to be explored in future
research. The currently still largely intact frontal prediction-error
signalling in the at-risk group speculatively may be a mechanism
that helps prevent a mild symptom becoming a severe one (e.g. a
suspicion becoming a delusion), although longitudinal studies
would be required to test such a mechanistic hypothesis.
Our study was not designed to be sensitive to prediction-error
signalling in all cortical regions, and would be unlikely to be
sensitive to auditory cortex predictive signals that have been
implicated in the generation of auditory hallucinations [54, 55]. It
would therefore be premature to conclude that all cortical
prediction-error signalling is intact in at-risk patients. We note
that two previous studies found preliminary evidence (not
corrected for multiple comparisons) of enhanced frontal activation
anticipating a reward in clinical risk groups using the monetary
incentive delay paradigm [37, 38]. Although these prior ﬁndings
may appear to contrast with our results of intact activation in the
dorsolateral prefrontal cortex in the at-risk group, the studies are
consistent in showing more prominent sub-cortical reductions in
signalling in the at-risk state with no evidence of cortical
reductions.
The probabilistic map of the dopaminergic midbrain, we used
to assess midbrain activation [46], has been used in a number of
prior studies [47, 48]. It combines the substantia nigra and the
VTA; however, we did not seek to differentiate these structures.
Differentiating activation amongst midbrain nuclei is generally
challenging and conﬁrmation of the precise anatomical abnorm-
alities in psychosis could be facilitated with future developments
in MRI technology such as the use of higher ﬁeld strengths. We
emphasise here that our results pertain to the region of the
dopaminergic midbrain, acknowledging that the distinction
between the substantia nigra and VTA is challenging in fMRI as
well as that fMRI does not demonstrate the neurochemical origin
of the signals observed. Our analysis of variance within a
combined limbic and associative striatal region of interest did
not demonstrate any voxels showing a signiﬁcant group
difference corrected for multiple comparisons. This could be due
to a lack of power, with a small sample size in the FEP group and
variable activation in the at-risk patients, or it could indicate areas
of relatively spared function in some patients [32, 56, 57, 51]. The
relatively small sample size, especially in the FEP group, is a
limitation of the study, which is relevant for all regions of interest.
In our study, we did not detect any signiﬁcant correlations
between neuroimaging metrics and symptom scores. Symptom
correlations often provide inconsistent results in schizophrenia
research [58]; a key reason for this inconsistency is the difﬁculty of
gathering a large enough sample, often requiring 50 or more
patients for reasonable power, which is rare in single site
neurobiology studies [58]. Therefore, our sample size is a clear
limitation to assess symptom correlations. Although the focus of
antipsychotic naive patients in the study is a strength in many
ways, it is also a limitation, as the study sample is not completely
representative of the entire population of ﬁrst-episode psychosis.
The combination of a requirement to have psychotic symptoms,
and to undertake a cognitive task (albeit a simple one) in a
scanner, but not be on antipsychotic medication, excludes some
of the most severe patients who are simply to unwell to
participate in this kind of research until their health improves on
treatment.
In the analysis of choice performance and reaction time data we
did not ﬁnd any signiﬁcant group differences. Win-stay/lose-shift
analysis revealed that participants, independent of trial type
(reward, bivalent or neutral), have a signiﬁcantly higher probability
to repeat the same response after a win than to shift after a loss,
which is a clear indication for engagement and learning in a
probabilistic learning task [59, 60]. The win stay probability was
highest on reward trials, as expected, as these trials are the most
predictable and consistently rewarding. However, also the win
stay probability on bivalent trials shows that participants were
engaging in the task and attempting to apply a learning strategy.
The neutral trials show a lower probability rates and a less clear
model learning behaviour. This, however, is not important for our
analysis, as neutral trial imaging correlates are covariates of no
interest. This analysis revealed subtle behavioural differences
between the controls and the FEP patients: FEP patients have
lower probabilities to repeat a response that lead to a win and a
higher probability to shift after a loss, showing less stability in their
decision making process.
An advantage of our study is that we use a paradigm that can
generate assays of prediction-error signalling either by a
traditional cognitive subtraction fMRI approach or by a
computational modelling fMRI approach (Supplementary Mate-
rial) as previously applied by others and ourselves [11, 12, 41,
59]. The convergent results indicate that the ﬁndings are not
secondary to particular modelling strategy supplied, and are not
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confounded by outcome valence, which is often highly collinear
with prediction error in many reinforcement learning studies,
which has been raised as a concern raised by some researchers
previously [43].
In conclusion, we document midbrain and cortical deactivations
in prediction-error signals in antipsychotic naive FEP patients,
supporting previous ﬁndings, and extending these to an
antipsychotic naive sample. The ﬁndings in our at-risk group
suggest a more nuanced account of the pathogenesis of
symptoms. In the at-risk group, there was midbrain evidence of
dysfunction intermediate between controls and FEP, but relatively
spared DLPFC function in contrast to frank psychosis. Further
investigations into areas of continuity and discontinuity between
the at-risk and frank psychosis patients, including longitudinal
designs, may bring insights into factors critical in the pathogenesis
of psychotic illness.
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